AlphAIalphai — Financial news for AI agents
fool.comAUG 193 min read$LQDA

Liquidia (LQDA) Q2 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q2 2026 earnings with YUTREPIA net sales at $170.4M, up 31% QoQ. Net income was $74.7M ($0.74/diluted share). The company guided 2027 revenue to exceed $1B. R&D expenses rose 185% YoY due to L606 program costs. Management highlighted strong patient adoption and market share growth.

Original reporting
fool.com
Published Aug 19, 2026, 2:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 2:33 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Liquidia (LQDA) Q2 2026 Earnings Call Transcript — source image
Source · fool.com
Decision brief

The 30-second read

$LQDABullishHigh
01

Why it matters

Earnings beat expectations and strong guidance suggest upside potential, but litigation and trial risks remain.

02

Market read

First‑time disclosure of quarterly performance and 2027 guidance for a small‑cap biotech, offering actionable insight for traders.

03

What to watch

Potential litigation risk from 327 patent case could affect future cash flow.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Liquidia Corporation reported its Q2 2026 financial results and updates on its YUTREPIA product and L606 pipeline.

Company-level read

Ticker impact

$LQDABullishHigh confidence
Context

Q2 2026 earnings release shows $170.4M product sales, $74.7M net income and $1B+ 2027 revenue guidance.

Expected impact

Potential near‑term rally as investors price in higher revenue outlook.

Evidence & confidence

Quarterly results exceed prior expectations and include a $1B+ revenue target for 2027, indicating sustained growth.

Market effects

Sector

Boosts outlook for pulmonary hypertension therapeutics and inhaled drug segment.

Regional

Positive for US biotech investors.

Global

Limited to specialty pharma niche.

Counterpoint

What could challenge this read

If trial enrollment slows, guidance may be overly optimistic.

Key entities

  • Company
    Liquidia Corporation

    US‑listed biotech delivering inhaled treprostinil therapy.

  • Product
    YUTREPIA

    Inhaled treprostinil for PAH and PH‑ILD.

Read at source← All news

Related articles

AUG 31
$LQDAMed

Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?

Liquidia Corporation (LQDA) is relying on Yutrepia, its inhaled dry-powder treprostinil therapy, to drive growth despite intense competition in the PAH market. Yutrepia generated $300.3M in sales in H1 2026 and has seen strong adoption. LQDA faces competition from United Therapeutics (UTHR) and Insmed (INSM), with UTHR expanding its PAH franchise. LQDA's shares have surged 96.3% YTD, trading at 6.16X forward sales. Analysts have lowered EPS estimates for 2026 and 2027.

tradingview.com2 min
AUG 13
$LQDAMedAI 8/10

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Liquidia (LQDA) reported Q2 2026 EPS of 74 cents, above the Zacks estimate of 70 cents. Revenues rose to $171.7 million from $8.8 million a year earlier, beating the $165 million consensus, driven by Yutrepia net product sales of $170.4 million. Shares fell about 10% after results. Liquidia said it targets over $1 billion net revenues in 2027.

tradingview.com7 min
AUG 12
$LQDAMed

Liquidia Corp (LQDA): Results of Operations and Financial Condition

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 · Approximately 5,900 unique patient

SEC EDGAR 8-K6 min
JUN 4
$LQDAMedAI 8/10

Liquidia (NASDAQ:LQDA) Shares Up 14.9% – What’s Next?

Liquidia (NASDAQ:LQDA) shares rose 14.9% to about $64 in mid-day trading Thursday after closing at $55.69; the stock traded as high as $62.20 on lighter volume (779,911 shares vs. 1.67M average). The May 11 quarter beat estimates: EPS $0.52 vs. $0.41; revenue $132.87M vs. $119.44M. Analysts’ targets ranged from $19 to $70.

themarketsdaily.com5 min